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Objective/background: Tuberculosis remains an important cause of mortality worldwide.
Previous tuberculosis treatment is a strong determinant of multi-drug resistant tuberculo-
sis. The study objective was to describe the mutations detected of Mycobacterium tuberculo-
sis (MTB) complex clinical strains screenedwith GeneXpert isolated from previously treated
patients in Coˆte d’Ivoire.
Methods: Sputumcollected anddecontaminated by then-acetyl-L-cysteinemethodwasused
to perform Ziehl–Neelsen staining, GeneXpert MTB/rifampicin, and culture on Lowenstein–
Jensenmedium. Drug susceptibility testing (DST) for first-line drugswas performed in a Bac-
tec 960 Automated System. After strain identification by antigen MPT64 detection, DNA
extraction, and genotyping with MTBDRplus assay was performed and interpreted. The
strains muted in rpoB without a specific protein identified and were sequenced.
Results: Mutant sequenceswere detected in 60 sputum sampleswith GeneXpert MTB/rifam-
picin of which 55 were confirmed multi-drug resistant MTB strains after DST. The most fre-
quent mutations responsible for rifampin resistance were detected with MTBDRplus assay
for 49 (81.7%) clinical strains, while sequencing was required for 11 (18.3%). H526Qmutation,
L533P, and D516V associated respectively with L533P, A532A, and S522L, and were observed
for three relapse cases. For these cases, GeneXpert and sequencing resultswere concordant.
Discrepancies betweenGeneXpert andmycobacteria growth indicator tube-DST for rifampin
were observed for three strains, on which D516Y, H526C, and L533P were identified.
Conclusion: In the setting of a high prevalence of drug resistance, characterization of the
genetic basis of MTB strains resistant to rifampin could be screened first with MTBDRplus.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier
Ltd. All rights reserved.Introduction
Tuberculosis remains an important cause of morbidity and
mortality worldwide [1]. The development of multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at
least isoniazid (INH) and rifampin (RMP) [2] represents a pub-
lic health concern and threatens global TB control programs
[3]. A variety of reasons may explain the emergence of
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tion of treatment, inappropriate treatment, poor monitoring
of patients under treatment, etc.). The World Health Organi-
zation (WHO) report 2013 estimated that MDR-TB cases
among new and previously treated cases were 3.6% and
20.2%, respectively [1]. Sub-Saharan Africa shows the highest
incidence of TB with 1.3 million new cases per year [1]. As in
many Sub-Saharan African countries, TB is a major health
problem in Coˆte d’Ivoire. In fact, 25,299 TB cases were notified
in 2013: that represents an estimated incidence of 106/100,000
population. The MDR-TB cases are estimated to be 2.5% and
53.2%, respectively, for new and previously treated cases
[4,5]. RMP and INH are the cornerstone current TB treatment.
As RMP resistance is a good surrogate marker for multidrug
resistance (MDR) [6,7], the rapid detection of the mutations
in a specific genomic region (RMP resistance-determining
region) can contribute to a fast diagnosis of MDR-TB, allowing
the initiation of an appropriated treatment. Several methods
for rapid drug resistance detection have been validated [8].
GeneXpert MTB/rifampicin (RIF) assay endorsed by WHO [9]
is one of the most used in routine analysis to confirm active
TB cases and to detect mutations conferring RMP resistance.
This study objective was to characterize the mutations of
MTB complex clinical strains screened with GeneXpert
(Cepheid, Inc., Sunnyvale, CA, USA).Materials and methods
Sputum samples from 63 pulmonary TB cases smear positive
(failure, relapse, defaulter) were recruited in the Reference
Regional Center for TB and in the Teaching Hospital of Cocody
and Treichville.
For each patient enrolled, two sputum samples were col-
lected and transported at 4 C in an icebox to the National
Reference Tuberculosis Laboratory at Institut Pasteur de Coˆte
d’Ivoire.
Manipulations of infectious clinical specimens were per-
formed in a Class II safety cabinet in a BLS3 laboratory.
According to the WHO standard recommended procedures
[10] (reference), sputum samples were decontaminated with
N-acetyl-L-cystein, 4% NaOH-2.9% citrate (final concentration
of NAOH 1%), followed by an incubation period at room tem-
perature of 15 min. Sputum samples were centrifuged at
3000g for 20 min. The supernatant of concentrated sputum
were carefully eliminated. The pellet was resuspended with
2 mL of sterile phosphate buffer.
The GeneXpert MTB/RIF assay was performed according to
manufacturer instructions. The GeneXpert MTB/RIF assay
definition files version 4.4a was used. Data analysis for RMP-
resistance detection was reported with cycle threshold differ-
ences superior to 4.5 as suggested by the manufacturer.
One hundred microliters of resuspended pellet were used
to perform a smear which was stained by the Ziehl–Neelsen
method. Two hundred microliters of suspension were inocu-
lated on two Lowenstein–Jensen tubes and incubated at
37 C for 6 weeks. Positive cultures were examined for acid
fast bacilli detection using Ziehl–Neelsen staining. For diagno-
sis of MTB complex, detection of MPT64 was done in accor-
dance with the manufacturer’s procedure SB (StandardDiagnostics, Seoul, South Korea). Mycobacterium Growth
Indicator Tube 960 automated drug susceptibility testing
(MGIT-DST) was performed for first- and second-line drugs
according to the Becton Dickinson product and procedure
manual (BD Biosciences, Sparks, MD, USA). SIRE kit procedure
(MGIT, Becton-Dickinson) was used for first-line drugs. The
critical concentration of each drug was 1.0 lg/mL, 0.1 lg/mL,
1.0 lg/mL, and 5 lg/mL respectively for streptomycin, INH,
RMP, and ethambutol. MGIT tubes inoculated were incubated
in the automated MGIT 960 for 12 days.
For each DST validated, 100 mL of the negative control
were transferred in 1,500 lL eppendorf tube containing Tris-
ethylenediaminetetraacetic acid. Bacterial suspension was
resuspended by vortexing and was inactivated at 95 C for
20 min. MTB complex strains inactivated were incubated in
ultrasonic bath for 15 min and centrifuged at 13,000g for
5 min. Supernatant containing DNA was transferred into a
fresh tube. For DNA extraction, a negative control was
included in each run.
With DNA extracted, Genotype MTBDRplus assay version
2.0 (Hain Lifescience, Nehren, Germany) was performed as
recommended by the manufacturer. The amplification mix-
ture contained 35 lL of primer-nucleotide Mix B, 10 lL of
Mix A (5 lL 10 polymerase chain reaction buffer, 2 lL of
MgCl2, 3 lL of molecular water, 1 unit of thermostable Taq
DNA polymerase), and 5 lL of extracted chromosomal DNA
solution.
Amplification parameters used were: 15 min of denatura-
tion at 95 C, followed by 20 cycles of 30 s at 95 C, and
2 min at 65 C, followed by 30 additional cycles of 25 s at 95 
C, 40 s at 53 C, and 40 s at 70 C, ending with a final extension
step of 8 min at 70 C (1 cycle).
Hybridization and detection were performed with a
TwinCubator (Hain Lifesciences GmbH, Germany) semi-
automatedwashing and shaking device according to theman-
ufacturer’s instructions and using the reagents provided with
the kit. Twentymicroliters of denaturation solutionwasmixed
to 20 lL of amplified sample. Mixed solution was incubated at
room temperature for 5 min. One milliliter of prewarmed
hybridization buffer was added before the membrane strips
were placed and shaken in the hybridization solution for
30 min at 45 C. After two washing steps, a colorimetric detec-
tion of the hybridized amplicons was obtained by the addition
of the streptavidin alkalinephosphatase conjugate.
An internal quality control process with positive and neg-
ative controls was implemented during the study. An inter-
pretable MTBDRplus assay was defined as a test strip with
all control markers positive, including results of the markers
for positive control (H37Rv strain), and negative control for
DNA extraction and for mix preparation.
Strains with a mutation in the rpoB gene without specific
protein detected were inactivated in ethanol (70%) and sent
to Supranational Laboratory of Milan (Italy). Sequencing of
the rpoB gene was performed. After sequence analysis and
interpretation, the results obtained were sent to the National
Reference Tuberculosis Laboratory located at Institut Pasteur
de Coˆte d’Ivoire.
Data were entered in Microsoft Office Excel 2013. The gold
standard for RMP susceptibility was MGIT 960 automated DST.
Descriptive analysis was done based on data.
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Sixty-three patients were recruited in different areas (North,
West, South, East, Center) of Coˆte d’Ivoire. Of the 63 patients
enrolled, 27 did not live in the Abidjan District. The mean age
of patients was 32.6 ± 11 years. The youngest and oldest
patients were aged 15 years and 73 years, respectively. Failure
cases were 44, of which nine were co-infected (TB/human
immunodeficiency virus-1). In this group the number of male
patients was twice as high as women patients. Direct exami-
nation after Ziehl–Neelsen staining was negative for two clin-
ical failure cases.
The second group was composed by 19 patients, of whom
17 and two were relapse cases and defaulters, respectively. Of
the six women, one case of co-infection (TB/human immun-
odeficiency virus-1) was identified. The presence of acid fast
bacilli was detected in the sputum of 18 patients (Table 1).
Of the 63 patients enrolled, 32 (88.9%) and 23 (85.2%) living
in the Abidjan District and outside, respectively, were infected
by MTB strains resistant to at least to RMP and INH (Table 2).
Of the 63 GeneXpert MTB/RIF assays performed, curve
amplification analyzed revealed that probes B did not bind to
the mutant sequence for 24 sputum samples. Mutations
detected interpreted as resistant to RMP was confirmed for 23
isolates with MGIT RMP susceptibility testing. Resistance to
INH was also confirmed for these 23 clinical isolates (Table 2).
Among the three sputum samples for which five probes
were bound to wildtype, a mutation in the rpoB gene was
detected for one. This last molecular result and DST in liquid
medium (RMP) were concordant (Table 2).
For one sputum sample, none of the five probes of GeneX-
pert MTB/RIF assay bound to a wildtype sequence. Culture
performed on Lowenstein–Jensen was positive and permitted
to identify a strain of MTB complex. The clinical strain was
pan-susceptible for drugs tested (Table 2).Table 1 – Socio-demographic, Clinical, and Bacteriologic Charac
Data Failure cases
Male Female Tota
Sex 30 14 44
HIV status
HIV1 positive 5 4 9
HIV negative 25 8 33
Unknown – 2 2
Residence
Abidjan’s District 14 9 23
Outside of Abidjan 16 5 21
Smear examination (Ziehl–Neelsen)
No AFB 1 1 2
Scanty – – –
1+ 5 6 11
2+ 12 1 13
3+ 12 6 18
Note: AFB = acid fast bacilli; HIV = human immunodeficiency virus.In total, discrepancies between GeneXpert MTB/RIF assay
and MGIT RMP susceptibility testing were observed for four
(6.3%) samples (Table 2).
Among the patients included, hybridization of DNA
extracted from the strains showed a D516V, H526D, H526Y,
and S531L mutation in the rpoB gene for 23, six, nine, and
11 patients, respectively (Table 3). Sequencing of the rpoB gene
realized on eight strains revealed an insertion 1542TTC
(codon 514), several punctual mutations at codon 526, and
two mutations at the codon 533 (Table 4).
Nine strains with a S531L mutation in the rpoB gene asso-
ciated with a S315T mutation in the katG gene were observed.
For one of them, phenotypic and molecular results were dis-
cordant (Table 3).
Discrepancies between phenotypic and molecular meth-
ods were also observed for three others cases. For two of
them, mutant sequences did not hybridize with the probes
7 and 3–4, respectively (Table 3).
A clinical strain with mutant sequences detected using
GeneXpert MTB/RIF assay (probe E) and MTBDRplus assay
(probe 8) was interpreted susceptible with a phenotypic
method (Tables 2 and 3). Sequencing of the rpoB gene revealed
a L533P mutation (Table 4).
Sequencing of the rpoB gene permitted the detection of
D516Y and H526C mutations. Of the 11 strains sequenced,
three had a double mutation. For one of them, probe E did
not bind to the mutant sequence (Table 4).
Hybridization by MTBDRplus assay permitted the charac-
terization of 49/60 (81.7%) of the mutations occurring in the
rpoB gene, while sequencing was required for 11 (18.3%)
(Tables 3 and 4). Probes B and D did not bind to mutant
sequences of one strain (Table 2). MTBDRplus assay revealed
an absence of hybridization with probe 7. Specific proteins
excreted were not detected. The sequencing of the rpoB gene
detected a H526G mutation (Table 4).teristics of Patients Recruited.
Others (relapse cases, defaulters)
l Male Female Total
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As a major public health problem, TB stands in the way of
development. Also, a major emphasis has been given on the
rapid diagnosis of TB, notably MDR-TB. GeneXpert MTB/RIF
is one of the molecular methods most used because the tool
is sensitive, specific, and relatively easy to perform [11–13].
Discordant results between genotypic and phenotypic
methods concerning RMP sensitivity were described [14]. In
this study, four cases were reported of which one had a
S531L mutation.
This mutation is one of the most frequently described and
is well correlated with RMP phenotypic resistance [15,16].
Here, discrepancies between phenotypic and molecular
methods may be due either to technical errors that occurred
in the strain suspension preparation before inoculation of
MGIT or a problem with dysgonic strains and the gold stan-
dard used [14,17].
The three other (D516Y, H526C, and L533P) mutations in
the rpoB gene give frequent discrepancies between genotypic
and phenotypic methods [17]. Nevertheless, for some authors,
these mutations are concordant with phenotypic resistance
to RMP [18,19]. The three clinical strains were isolated from
failure cases after a 2RHZE/2RH regimen. That strongly sug-
gests of drug resistance.
The katG S315T mutation induces a high level resistance to
INH and it is well correlated with phenotypic resistance
[20,21]. For one clinical strain carrying the rpoB H526Y muta-
tion associated with the katG S315T mutation, DST for INH
was interpreted susceptible (Table 3). This situation might
be explained by the slow growth of MTB strains in the tube
containing INH comparatively to other tubes inoculated.
For characterization of resistance detected using real-
time polymerase chain reaction, we performed MTBDRplus
assay on strains. Of the 60 strains with a mutation in the
rpoB gene, 81.7% of them had a punctual mutation identi-
fied with this method. These mutations are the most
described encoding for RMP resistance [15,16]. For 18.3%,
although the method has permitted the detection of the
presence of a mutant sequence, a specific protein was not
identified. Sequencing of the rpoB gene was required. The
GeneXpert MTB/RIF and MTBDRplus screen the same frag-
ment of 81 bp of the rpoB gene. In fact, the mutations
detected by the two methods are localized on the same
position. This is clearly demonstrated with the three strains
for which a double mutation has been detected in the rpoB
gene by sequencing comparatively to GeneXpert MTB/RIF
probes analysis (Table 3). In fact, for GeneXpert MTB/RIF
probes B, C, D, and E screen the same position respectively
for MTBDRplus the probes 3 + 4, 5 + 6, 7, and 8. For the
silent mutation (A532A) associated with rpoB L533P, codon
532 is closed to 533 and the same probe E that did not bind
to the mutant sequence detects them. This is the main rea-
son why GeneXpert MTB/RIF has detected three double
mutations. Unfortunately, probes C and D did not bind to
the mutant sequence. Hybridization and sequencing
revealed a mutant sequence only for the probe D character-
ized with H526G mutation (Table 3). This may be due to
contamination that occurred during the inoculation of the
Table 3 – Mutations described and drug susceptibility testing results for failure cases.
Patterns of mutations detected No. of clinical isolates Drug susceptibility testing
RMP (1 lg/mL) INH (0.1 lg/mL)
rpoB gene katG gene inhA promoter R S R S
D516V S315T wt 8 8 – 8 –
D516V S315T T8A 8 8 – 8 –
D516V S315T T8C 7 7 – 7 –
Dwt 3 S315T wt 1 1 – 1 –
Dwt 3-4 S315T wt 1 – 1 1 –
Dwt 3-4-5-6 S315T wt 1 1 – 1 –
Dwt 7 S315T wt 3 2 1 3 –
Dwt 7 S315T T8C 1 1 – 1 –
Dwt 7-8 S315T wt 1 1 – 1 –
H526D S315T wt 2 2 – 2 –
H526D S315T T8C 4 4 – 4 –
H526Y S315T wt 4 4 – 3 1
H526Y S315T T8A 2 2 – 2 –
H526Y S315T T8C 3 3 – 3 –
S531L wt wt 1 1 – 1 –
S531L S315T wt 9 8 1 9 –
S531L S315T T8C 1 1 – 1 –
Dwt 8 S315T wt 2 1 1 2 –
Dwt 8 S315T T8A 1 1 – 1 –
wt wt wt 3 – 3 – 3
Note: Dwt = no hybridization with wildtype probes and absence of specific mutation detected; INH = isoniazid; R = resistant; RMP = rifampin;
S = susceptible; wt = wildtype.
Table 4 – RpoB Gene Sequencing Results.
Size Wildtype patterns of rpoB gene Sequencing results
Failures cases (n = 8) Others cases (n = 3)
1 Dwt 3 Ins 1542 TTC –
1 Dwt 3-4 D516Y –
1 Dwt 3-4-5-6 – D516E & S522L
4 Dwt 7 H526C –
H526G –
H526L –
H526 N –
1 Dwt 7, 8 – H526Q & L533P
3 Dwt 8 L533P A532A & L533P
Note: Dwt = no hybridization with wildtype probes and absence of specific mutation detected.
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may also explain this observation [22,23]. Indeed, DST was
performed from cultures obtained on Lowenstein–Jensen.
Contrary to the other mutations interpreted as resistant to
RMP with GeneXpert MTB/RIF, for the sample of one relapse
case, the five probes were bound to a mutant sequence. Anal-
ysis of the amplification curves showed that the earliest and
latest threshold were at the 18 cycles and 29 cycles, respec-
tively, for probe A and B. GeneXpert has permitted the identi-
fication of a hetero-resistance case that was not confirmed by
MDTBRplus. Indeed, a D516V mutation was clearly detected.
This difference might be in relation with the samples used
for the assays (sputum for GeneXpert and strain for
genotyping).Previous treatment for TB is a strong determinant of
MDR-TB [24,25]. Of the 60 previously treated patients with
a mutation in the rpoB gene, phenotypic results permitted
the confirmation of 55 MDR-TB cases. Patients were
recruited in different regions of the Coˆte d’Ivoire and most
of them excreted bacilli. They represent an important way
of MDR-TB strain dissemination in communities, particu-
larly in low-income countries where there is not an ade-
quate structure for their care. Therefore, directly observed
treatment represents one of the best ways to treat and pre-
vent propagation of resistant strains in communities.
In summary, MDR strains were identified in most of the
previously treated patients. MTBDRplus assay has permitted
the characterization of the genetic basis of RMP resistance
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18.3% of patients sequencing was required.
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